Insmed Drug Wins First US Approval for Debilitating Lung Disease
The once-daily pill, called Brinsupri and known chemically as brensocatib, eases bronchiectasis, a chronic inflammatory disease that damages the airways and can make it hard to breathe. Patients struggle to clear mucus from their lungs, which creates a breeding ground for infections and often lands them in the hospital for long periods.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
35 minutes ago
- New York Post
Texas woman claims US Marine got her pregnant, then spiked her drink with abortion pills after she refused to ‘get rid of it': lawsuit
A Texas woman claims a US Marine got her pregnant and then secretly spiked her hot chocolate with abortion pills — ending her pregnancy without her consent after she refused his repeated demands to 'get rid of it,' according to a federal lawsuit. Liana Davis filed the wrongful death suit Monday, accusing Christopher Cooprider, 34, of dissolving at least 10 misoprostol pills into a drink he gave her at her Corpus Christi home on April 5 while she was eight weeks pregnant with his child, according to the lawsuit obtained by The Post. Liana Davis accused Christopher Cooprider of dissolving at least 10 misoprostol pills into a drink he made for her at her Corpus Christi home on April 5 while she was eight weeks pregnant with his child. Getty Images Advertisement Within 30 minutes of drinking the hot chocolate, Davis began 'hemorrhaging and cramping,' while Cooprider allegedly fled the scene and stopped responding to texts, the suit — filed in the US District Court for the Southern District of Texas — claimed. 'I am gushing blood. Please hurry,' Davis texted him around 12:30 a.m. Instead, Davis's disabled mother had to take an Uber to watch her three sleeping children while a neighbor rushed the bleeding woman to the hospital. Her unborn baby, whom she had already named Joy, did not survive, documents said. Advertisement The lawsuit also alleges Cooprider ordered the abortion pills without Davis' knowledge or consent from Aid Access, an international online pill provider founded by Dutch physician Dr. Rebecca Gomperts. Both Aid Access and Gomperts were also named as defendants in the lawsuit. The alleged drink spiking followed a months-long campaign by Cooprider, a Marine pilot in training who was temporarily stationed in Corpus Christi, to pressure Davis into an abortion after she told him she might be pregnant in late January, according to the suit. 'We're not in love,' he texted her after the pregnancy was confirmed. 'It would be messed up to bring a child into the world without both parents raising them,' he said, the suit claimed. Cooprider continued to tell David to 'get rid of it' after her pregnancy test came back positive — causing her stress. Advertisement 'Every time you say 'get rid of it,' it's like an electric shock,' she wrote, according to the lawsuit. 'I literally feel like I'm going down the steepest hill on a roller coaster when I read that.' The lawsuit also alleges Cooprider ordered the abortion pills without Davis' knowledge or consent from Aid Access, an international online pill provider founded by Dutch physician Dr. Rebecca Gomperts. AP Cooprider even brought abortion pills to Davis' house several times to ask her to 'kill' her unborn baby, the suit said. He would leave the pills behind, hoping Davis would change her mind, she alleged. Despite several heated text exchanges, Cooprider failed to convince Davis to have the abortion. The Marine even threatened to testify against her in a custody battle for her three children with an ex-husband, Davis claimed. Advertisement By April, Cooprider appeared to change his tune, proposing that they have a 'trust-building' night where they'd drink warm tea and reconnect. Instead, three days later, he allegedly served her the poisoned hot cocoa. When Davis returned home from the hospital, she found the open box of abortion pills, which she handed over to Corpus Christi police. Despite the allegations, Corpus Christi police said there is no active investigation into Cooprider, NBC reported. The lawsuit seeks Cooprider, Aid Access, and Gomperts to pay undisclosed damages for the wrongful death of Davis's unborn child.
Yahoo
37 minutes ago
- Yahoo
How a bowel cancer examination revealed AI's negative impact on doctors
Using AI regularly can potentially 'deskill' health workers, a new study suggests. Academics said that the finding is 'concerning' given the rapid uptake of artificial intelligence (AI) across healthcare. The new study looked at health workers who perform a test to look for early signs of bowel cancer. Endoscopists perform a test called a colonoscopy to look for precancerous growths in the bowel known as adenomas. This means these pre-cancerous growths can be detected and removed, preventing them from becoming bowel cancer. Advances in AI technology have led to the development of computer-assisted polyp detection systems, which have been found to help these health workers spot more adenomas. Researchers wanted to assess whether continuous use of AI led to a dip in performance when endoscopist perform colonoscopies without AI by analysing work conducted in Poland. The research team analysed 1,442 colonoscopies conducted by experienced health workers before and after AI systems were rolled out at certain centres in 2021. Writing in the journal Lancet Gastroenterology and Hepatology, researchers reported that the rate of detection of polyps was 6 per cent lower after the introduction of AI in standard and non-AI assisted colonoscopies. 'To our knowledge this is the first study to suggest a negative impact of regular AI use on healthcare professionals' ability to complete a patient-relevant task in medicine of any kind,' said one of the study authors, Dr Marcin Romanczyk, Academy of Silesia in Poland. 'Our results are concerning given the adoption of AI in medicine is rapidly spreading. 'We urgently need more research into the impact of AI on health professional's skills across different medical fields. We need to find out which factors may cause or contribute to problems when healthcare professionals and AI systems don't work well together, and to develop ways to fix or improve these interactions.' In a linked editorial, Omer Ahmad, a consultant gastroenterologist and interventional endoscopist and clinical research fellow at University College London, wrote: 'These findings temper the current enthusiasm for rapid adoption of AI-based technologies such as CADe and highlight the importance of carefully considering possible unintended clinical consequences. 'The study provides the first real-world clinical evidence for the phenomenon of deskilling, potentially affecting patient-related outcomes.'
Business Upturn
39 minutes ago
- Business Upturn
Global High-Throughput Screening Market to Surpass USD 50.2 Billion by 2029
By GlobeNewswire Published on August 13, 2025, 05:30 IST Delray Beach, FL, Aug. 12, 2025 (GLOBE NEWSWIRE) — North America Leads Today, Asia Pacific to Record Fastest Growth The global high throughput screening market, valued at US$25.7 billion in 2023, stood at US$28.8 billion in 2024 and is projected to advance at a resilient CAGR of 11.8% from 2024 to 2029, culminating in a forecasted valuation of US$50.2 billion by the end of the period. This growth is propelled by surging R&D investments in drug discovery, strategic government funding, and the increasing adoption of automation in life sciences research. Download PDF Brochure: What Is Driving the Market Now? HTS adoption is accelerating due to innovations in automation, miniaturization, and high-content screening, which significantly reduce discovery timelines and enhance precision in identifying therapeutic candidates. Grants such as the USD 7.8 million awarded to the University of Pittsburgh for advanced drug discovery systems underscore growing institutional and government commitment to high-impact research. Why Does This Matter for Global Pharma and Biotech Leaders? The market represents a critical enabler for competitive advantage in lead discovery, target validation, compound profiling, and hit identification—processes essential for pipeline acceleration. While high instrument costs remain a barrier, particularly for automated liquid handling and high-resolution imaging systems, emerging markets such as China and India offer lucrative opportunities with strong government support and an expanding pharmaceutical manufacturing base. Who Are the Key Stakeholders? The HTS ecosystem spans pharmaceutical giants, biotechnology innovators, academic institutions, and technology providers, all collaborating to enhance assay development and manage the rising complexity of biological data. The consumables segment—driven by recurring purchases of reagents and kits—dominates the market, ensuring steady demand as HTS workflows expand globally. Request Sample Pages: Where Is Growth Coming From? North America currently leads, fueled by advanced HTS infrastructure, robust funding for life science research, and a thriving biotech sector. Asia Pacific is projected to be the fastest-growing region, supported by a diverse patient base, strong pharmaceutical capabilities, and favorable regulatory environments. How Are Market Leaders Responding? Thermo Fisher Scientific Inc. maintains global leadership through an extensive portfolio of automated systems, screening instruments, and consumables, underpinned by 3% annual R&D investment and strategic alliances. Agilent Technologies, Inc. offers highly customizable workflows via BioTek detection instruments and Gen6 software, strengthened by acquisitions such as e-MSion (US) to enhance mass spectrometry capabilities. Merck KGaA delivers a diverse portfolio of reagents, instruments, software, and services, leveraging global reach and deep customer relationships across pharma, academia, and government sectors. Market Outlook As automation, AI-driven data analysis, and advanced assay development converge, HTS will remain at the forefront of pharmaceutical innovation. Decision-makers who strategically invest in HTS capabilities today will be best positioned to accelerate therapeutic pipelines, capture market share, and deliver faster, more targeted treatments to market. For more information, Inquire Now Discover Connected Healthcare Market Opportunities: Drug Screening Market Carrier Screening Market Cell based Assays Market Label Free Detection Market Life Science Instrumentation Market Get access to the latest updates on High-Throughput Screening Companies and High-Throughput Screening Market Size Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
